Advanced search
Publication Cover
Hematology Volume 27, 2022 - Issue 1
Submit an article Journal homepage
1,624
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Efficacy and safety of plasmapheresis without plasma transfusion tandem with chemotherapy to treat multiple myeloma

Yigang Guoa Department of Hematology, Taihe Hospital, Hubei University of Medcine, Hubei, People’s Republic of ChinaView further author information
,
Lulu Zhanga Department of Hematology, Taihe Hospital, Hubei University of Medcine, Hubei, People’s Republic of ChinaView further author information
,
Rongyao Zhanga Department of Hematology, Taihe Hospital, Hubei University of Medcine, Hubei, People’s Republic of ChinaView further author information
,
Meiling Zhoua Department of Hematology, Taihe Hospital, Hubei University of Medcine, Hubei, People’s Republic of ChinaView further author information
,
Xu Chena Department of Hematology, Taihe Hospital, Hubei University of Medcine, Hubei, People’s Republic of ChinaView further author information
,
Chucheng Wana Department of Hematology, Taihe Hospital, Hubei University of Medcine, Hubei, People’s Republic of ChinaView further author information
,
Ping Hua Department of Hematology, Taihe Hospital, Hubei University of Medcine, Hubei, People’s Republic of ChinaView further author information
,
Yuanyuan Hea Department of Hematology, Taihe Hospital, Hubei University of Medcine, Hubei, People’s Republic of ChinaView further author information
,
Hua Jianga Department of Hematology, Taihe Hospital, Hubei University of Medcine, Hubei, People’s Republic of ChinaView further author information
,
Wei Genga Department of Hematology, Taihe Hospital, Hubei University of Medcine, Hubei, People’s Republic of ChinaView further author information
,
Weixing Zhangb Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong, University School of Medicine, Shanghai, People’s Republic of ChinaCorrespondence[email protected] [email protected]
View further author information
,
Fariha Kanwalc Department of Chemistry, Chemical Engineering, and Biotechnology, Donghua University, Shanghai, People’s Republic of ChinaView further author information
,
Muhammad Fayyaz ur Rehmand Institute of Chemistry, University of Sargodha, Sargodha, PakistanCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0003-2901-7212View further author information
ORCID Icon &
Zhangzhi Lia Department of Hematology, Taihe Hospital, Hubei University of Medcine, Hubei, People’s Republic of ChinaView further author information
 show all
Pages 1217-1222 | Published online: 11 Nov 2022

References

  • Costa LJ, Derman BA, Bal S, et al. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2020;1(1):35–13.
  • Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2021;18(2):71–84. doi:10.1038/s41571-020-0427-6
  • Rampersad C, Shaw J, Gibson IW, et al. Early antibody-mediated kidney transplant rejection associated with anti-vimentin antibodies: a case report. Am J Kidney Dis. 2020;75(1):138–143.
  • Rao A, Reddy A, Dinunno C, et al. Life-threatening hypertriglyceridemia-induced pancreatitis related to alectinib successfully treated by plasmapheresis: a review of the literature on metabolic toxicities associated with anaplastic lymphoma kinase inhibitors. J Oncol Pharm Pract. 2020;26(6):1533–1537.
  • Gill JC, Oakley DJ, Onwuemene OA. Strategies to aid identification of apheresis PowerFlow ports: a case report. J Emerg Nurs. 2021;47(1):21–27.
  • Goldschmidt H, Ashcroft J, Szabo Z, et al. Navigating the treatment landscape in multiple myeloma: which combinations to use and when? Ann Hematol. 2019;98(1):1–18.
  • Huang H, Feng Y-L, Wan T, et al. Effectiveness of sequential chemoradiation vs concurrent chemoradiation or radiation alone in adjuvant treatment after hysterectomy for cervical cancer: the STARS phase 3 randomized clinical trial. JAMA Oncol. 2021;7(3):361–369
  • Bridoux F, Arnulf B, Karlin L, et al. Randomized trial comparing double versus triple bortezomib-based regimen in patients with multiple myeloma and acute kidney injury due to cast nephropathy. J Clin Oncol. 2020;38(23):2647–2657.
  • Bridoux F, Leung N, Belmouaz M, et al. Management of acute kidney injury in symptomatic multiple myeloma. Kidney Int. 2021;99(3):570–580
  • Hutchison CA, Cockwell P, Moroz V, et al. High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial. Lancet Haematol. 2019;6(4):e217–e228.
  • Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood J Am Soc Hematol. 2020;136(1):71–80.
  • Korttila K, Gröhn P, Gordin A, et al. Effect of hydroxyethyl starch and dextran on plasma volume and blood hemostasis and coagulation. J Clin Pharmacol. 1984;24(7):273–282.
  • Marder V, Nusbacher J, Anderson F. One-year follow-up of plasma exchange therapy in 14 patients with idiopathic thrombocytopenic purpura. Transfusion. 1981;21(3):291–298.
  • Kaszuba-Zwoińska J, Gremba J, Gałdzińska-Calik B, et al. Electromagnetic field induced biological effects in humans. Przegl Lek. 2015;72(11):636–641.
  • Lemaire A, Parquet N, Galicier L, et al. Plasma exchange in the intensive care unit: technical aspects and complications. J Clin Apher. 2017;32(6):405–412.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.